PMPRB report reviews new drugs and their potential impact on future drug spending in Canada
The latest edition of Meds Pipeline Monitor provides stakeholders with a list of new medicines in the late stages of clinical evaluation that may significantly impact clinical practice or drug spending in the coming years.
Read the original at the source: https://www.canada.ca/en/patented-medicine-prices-review/news/2024/11/pmprb-report-reviews-new-drugs-and-their-potential-impact-on-future-drug-spending-in-canada.html
Officially imported this from Patented Medicine Prices Review Board’s own source. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- Patented Medicine Prices Review Board — imported from official source
- Official source
- https://api.io.canada.ca/io-server/gc/news/en/v2?dept=patentedmedicinepricesreviewboard&sort=publishedDate&orderBy=desc&publishedDate%3E=2021-07-23&pick=50&format=atom&atomtitle=Patented%20Medicine%20Prices%20Review%20Board ATOM
- Imported
- October 03, 2026 20:43
- Versions
- 1 recorded
- Identity
https://www.canada.ca/en/patented-medicine-prices-review/news/2024/11/pmprb-report-revi...